Omeros also has identified MASP-3 as the protein that is critical to the activation of the complement system’s alternative pathway in humans, which is linked to a wide range of immune-related ...

Please provide your email address to receive an email when new articles are posted on . Kim’s hypothesis arises partially from studies that showed that C3, when introduced to synthetic neutrophils, ...

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced publication of study results showing that inhibition of mannan-binding lectin-associated serine protease-2 (MASP-2) protects ...

Paraphrasing a line miscredited to Einstein: “Insanity is repeating the same mistakes and expecting different results.” With the just announced White House $5 Billion Covid-19 NextGen Project for ...

Dianthus achieved its NASDAQ listing last year via a merger with Magenta Therapeutics. The company is focused on development of a single drug candidate, DNTH-103, which targets the complement system, ...

Figure 1: Mannose-binding lectin (blue strands) can bind to sites on the SARS-Cov-2 spike protein on the cell membrane. One of the most striking features of the SARS-CoV-2 pandemic is that across all ...

Iron nanoparticles injected before magnetic resonance imaging can make tissues more visible and the same nanoparticles may allow doctors to precisely target tumors with new medicines. However, among ...

Please provide your email address to receive an email when new articles are posted on . A protein known as granzyme K was recently shown to be a driver of inflammation by activating the complement ...

(RTTNews) - Omeros Corp. (OMER), a clinical-stage biopharmaceutical company focused on complement-mediated diseases, oncology, and addictive disorders, today announced its financial results for the ...